clinical trial · NCT07647510
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Myasthenia Gravis, GeneralizedClaseprubartPlaceboClaseprubartPlacebo
brief summary
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
started
Jul 1, 2026
primary completion
Dec 1, 2028
completion
Sep 1, 2031
last updated
Jun 15, 2026
detailed description
The study includes the following periods:
* Screening (up to 12 weeks) * Randomized, blinded, controlled treatment (RCT) period (17 weeks) * Extended treatment period (ETP) (104 weeks) (optional) for eligible participants \[includes blinded extension period (BEP) and open-label extension (OLE) period\] * Safety Follow-Up period (40 weeks)
official title
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol